A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo
Pinheiro, Iris ![Identificador ORCID](/img/uab/orcid.ico)
(MRM Health NV)
Barberá Bellés, Aurora ![Identificador ORCID](/img/uab/orcid.ico)
(Hospital Universitari Vall d'Hebron)
Raurell, Imma (Hospital Universitari Vall d'Hebron)
Estrella, Federico (Hospital Universitari Vall d'Hebron)
de Leeuw, Marcel ![Identificador ORCID](/img/uab/orcid.ico)
(MRM Health NV)
Bolca, Selin (MRM Health NV)
Gottardi, Davide
(MRM Health NV)
Horscroft, Nigel
(MRM Health NV)
Possemiers, Sam
(MRM Health NV)
Salcedo, Maria-Teresa
(Hospital Universitari Vall d'Hebron)
Genescà Ferrer, Joan
(Hospital Universitari Vall d'Hebron)
Martell, María
(Hospital Universitari Vall d'Hebron)
Augustin Recio, Salvador
(Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona
Data: |
2022 |
Resum: |
The gut microbiome has a recognized role in Non-alcoholic fatty liver disease (NAFLD) and associated comorbidities such as Type-2 diabetes and obesity. Stool transplantation has been shown to improve disease by restoring endothelial function and insulin signaling. However, more patient-friendly treatments are required. The present study aimed to test the effect of a defined bacterial consortium of nine gut commensal strains in two in vivo rodent models of Non-alcoholic steatohepatitis (NASH): a rat model of NASH and portal hypertension (PHT), and the Stelic animal (mouse) model (STAM™). In both studies the consortium was administered orally q. d. after disease induction. In the NASH rats, the consortium was administered for 2 weeks and compared to stool transplant. In the STAM™ study administration was performed for 4 weeks, and the effects compared to vehicle or Telmisartan at the stage of NASH/early fibrosis. A second group of animals was followed for another 3 weeks to assess later-stage fibrosis. In the NASH rats, an improvement in PHT and endothelial function was observed. Gut microbial compositional changes also revealed that the consortium achieved a more defined and richer replacement of the gut microbiome than stool transplantation. Moreover, liver transcriptomics suggested a beneficial modulation of pro-fibrogenic pathways. An improvement in liver fibrosis was then confirmed in the STAM™ study. In this study, the bacterial consortium improved the NAFLD activity score, consistent with a decrease in steatosis and ballooning. Serum cytokeratin-18 levels were also reduced. Therefore, administration of a specific bacterial consortium of defined composition can ameliorate NASH, PHT, and fibrosis, and delay disease progression. |
Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Llengua: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Matèria: |
Bacterial consortium ;
Fibrosis ;
Gut microbiome ;
NAFLD ;
Portal hypertension |
Publicat a: |
Biomedicines, Vol. 10 (may 2022) , ISSN 2227-9059 |
DOI: 10.3390/biomedicines10051191
PMID: 35625927
El registre apareix a les col·leccions:
Articles >
Articles de recercaArticles >
Articles publicats
Registre creat el 2023-08-11, darrera modificació el 2024-05-22